The University of Texas MD Anderson Cancer Center and Nexo Therapeutics today announced a multi-year strategic collaboration that aligns the innovative technology and capabilities of each organization at the earliest stages of drug discovery and development to rapidly advance impactful new cancer therapies against previously undruggable targets.
DESTIN, Fla. — Low disease activity and remission are achievable for patients with lupus if clinicians “minimize the prednisone” and administer adequate hydroxychloroquine, noted a speaker at the 2023 Congress of Clinical Rheumatology-East.